NERV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NERV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Minerva Neurosciences's enterprise value is $-11.07 Mil. Minerva Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $3.47 Mil. Therefore, Minerva Neurosciences's EV-to-EBITDA for today is -3.19.
The historical rank and industry rank for Minerva Neurosciences's EV-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest EV-to-EBITDA of Minerva Neurosciences was 60.48. The lowest was -10.59. And the median was -6.55.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-12-14), Minerva Neurosciences's stock price is $2.21. Minerva Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.450. Therefore, Minerva Neurosciences's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Minerva Neurosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minerva Neurosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -3.07 | 35.30 | 0.59 | 1.12 | -0.10 |
Minerva Neurosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.07 | -0.10 | 0.73 | 0.35 | -2.26 |
For the Biotechnology subindustry, Minerva Neurosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Minerva Neurosciences's EV-to-EBITDA falls into.
Minerva Neurosciences's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -11.073 | / | 3.469 | |
= | -3.19 |
Minerva Neurosciences's current Enterprise Value is $-11.07 Mil.
Minerva Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minerva Neurosciences (NAS:NERV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Minerva Neurosciences's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.21 | / | -0.450 | |
= | At Loss |
Minerva Neurosciences's share price for today is $2.21.
Minerva Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Minerva Neurosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Ag Boehringer | 10 percent owner | BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216 |
Boehringer Ingelheim International Gmbh | 10 percent owner | 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166 |
Remy Luthringer | officer: EVP and Head of R&D | C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
Geoff Race | officer: EVP and CFO | C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
Frederick W Ahlholm | officer: Chief Accounting Officer | C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
David Kupfer | director | C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Joseph H. Reilly | officer: Chief Business Officer | C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
Van Heek G Jan | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
Richard E. Russell | officer: President | C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
William F Doyle | director | |
Hans Peter Hasler | director | C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Index Venture Associates Iii Ltd | 10 percent owner | 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG |
Index Venture Associates Iv Ltd | 10 percent owner | 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG |
From GuruFocus
By Marketwired • 08-06-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 05-01-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.